ARO-MAPT Early Trial Shows Up to 85% Individual Tau Reduction in Healthy Volunteers

Arrowhead Pharmaceuticals has released early clinical trial data: its experimental RNAi drug ARO-MAPT reduced tau protein levels by an average of 73% in the highest-dose group of healthy volunteers, with a maximum individual reduction of 85%. The article discusses whether the commercial logic of the tau target holds in Alzheimer's treatment.